drugset
drugset / Trial / NCT00428350

Study of Efficacy and Safety of Seroquel (Quetiapine Fumarate) as Mono-Therapy for Acute Schizophrenic

NCT00428350 ↗

Phase 4 Completed 120 enrolled AstraZeneca
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The primary objective of the study is to evaluate the efficacy of quetiapine fumarate (Seroquel) with daily dose 600mg-750mg used as mono-therapy in the treatment of acute schizophrenic patients by evaluation of the change from baseline in PANSS total score at Day 56 using the last observation carried forward (LOCF) method.

Timeline

Start
2006-12
Primary completion
2007-09
Completion
2007-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Quetiapine Small molecule 600 mg —
Subject Quetiapine Small molecule 750 mg —

Indications

schizophrenia